|
1
|
Shaikh AB, Li F, Li M, He B, He X, Chen G,
Guo B, Li D, Jiang F, Dang L, et al: Present advances and future
perspectives of molecular targeted therapy for osteosarcoma. Int J
Mol Sci. 17:5062016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
3
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jones KB: Osteosarcomagenesis: Modeling
cancer initiation in the mouse. Sarcoma. 2011:6941362011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li X, Jiang H, Xiao L, Wang S and Zheng J:
miR-200bc/429 inhibits osteosarcoma cell proliferation and invasion
by targeting PMP22. Med Sci Monit. 23:1001–1008. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Allison DC, Carney SC, Ahlmann ER,
Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A
meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu PK, Chen WM, Chen CF, Lee OK, Haung CK
and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis:
Clinical results and prognostic factors in 91 patients. Jpn J Clin
Oncol. 39:514–522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nandi D, Tahiliani P, Kumar A and Chandu
D: The ubiquitin-proteasome system. J Biosci. 31:137–155. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang LF, Zhang Z, Yang J, McLaughlin SH
and Barford D: Molecular architecture and mechanism of the
anaphase-promoting complex. Nature. 513:388–393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Passmore LA, McCormack EA, Au SW, Paul A,
Willison KR, Harper JW and Barford D: Doc1 mediates the activity of
the anaphase-promoting complex by contributing to substrate
recognition. EMBO J. 22:786–796. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sewart K and Hauf S: Different
functionality of Cdc20 binding sites within the mitotic checkpoint
complex. Curr Biol. 27:1213–1220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Zhang J, Wan L, Zhou X, Wang Z and
Wei W: Targeting Cdc20 as a novel cancer therapeutic strategy.
Pharmacol Ther. 151:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paul D, Ghorai S, Dinesh US, Shetty P,
Chattopadhyay S and Santra MK: Cdc20 directs proteasome-mediated
degradation of the tumor suppressor SMAR1 in higher grades of
cancer through the anaphase promoting complex. Cell Death Dis.
8:e28822017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marucci G, Morandi L, Magrini E, Farnedi
A, Franceschi E, Miglio R, Calò D, Pession A, Foschini MP and
Eusebi V: Gene expression profiling in glioblastoma and
immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch.
453:599–609. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mao Y, Li K, Lu L, Si-Tu J, Lu M and Gao
X: Overexpression of Cdc20 in clinically localized prostate cancer:
Relation to high Gleason score and biochemical recurrence after
laparoscopic radical prostatectomy. Cancer Biomark. 16:351–358.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Choi JW, Kim Y, Lee JH and Kim YS: High
expression of spindle assembly checkpoint proteins CDC20 and MAD2
is associated with poor prognosis in urothelial bladder cancer.
Virchows Arch. 463:681–687. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim Y, Choi JW, Lee JH and Kim YS: MAD2
and CDC20 are upregulated in high-grade squamous intraepithelial
lesions and squamous cell carcinomas of the uterine cervix. Int J
Gynecol Pathol. 33:517–523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu WJ, Hu KS, Wang DS, Zeng ZL, Zhang DS,
Chen DL, Bai L and Xu RH: CDC20 overexpression predicts a poor
prognosis for patients with colorectal cancer. J Transl Med.
11:1422013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang DZ, Ma Y, Ji B, Liu Y, Hwu P,
Abbruzzese JL, Logsdon C and Wang H: Increased CDC20 expression is
associated with pancreatic ductal adenocarcinoma differentiation
and progression. J Hematol Oncol. 5:152012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moura IM, Delgado ML, Silva PM, Lopes CA,
do Amaral JB, Monteiro LS and Bousbaa H: High CDC20 expression is
associated with poor prognosis in oral squamous cell carcinoma. J
Oral Pathol Med. 43:225–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding ZY, Wu HR, Zhang JM, Huang GR and Ji
DD: Expression characteristics of CDC20 in gastric cancer and its
correlation with poor prognosis. Int J Clin Exp Pathol. 7:722–727.
2014.PubMed/NCBI
|
|
23
|
Shi R, Sun Q, Sun J, Wang X, Xia W, Dong
G, Wang A, Jiang F and Xu L: Cell division cycle 20 overexpression
predicts poor prognosis for patients with lung adenocarcinoma.
Tumour Biol. 39:10104283176922332017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J,
Lu M, Peng S, Qiu J and Gao X: Silencing of CDC20 suppresses
metastatic castration-resistant prostate cancer growth and enhances
chemosensitivity to docetaxel. Int J Oncol. 49:1679–1685. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Xue YB, Li H, Qiu D, Wang ZW and
Tan SS: Inhibition of cell survival by curcumin is associated with
downregulation of cell division cycle 20 (Cdc20) in pancreatic
cancer cells. Nutrients. 9:E1092017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sackton KL, Dimova N, Zeng X, Tian W,
Zhang M, Sackton TB, Meaders J, Pfaff KL, Sigoillot F, Yu H, et al:
Synergistic blockade of mitotic exit by two chemical inhibitors of
the APC/C. Nature. 514:646–649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lub S, Maes A, Maes K, De Veirman K, De
Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, et
al: Inhibiting the anaphase promoting complex/cyclosome induces a
metaphase arrest and cell death in multiple myeloma cells.
Oncotarget. 7:4062–4076. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Lange J, Faramarz A, Oostra AB, de
Menezes RX, van der Meulen IH, Rooimans MA, Rockx DA, Brakenhoff
RH, van Beusechem VW, King RW, et al: Defective sister chromatid
cohesion is synthetically lethal with impaired APC/C function. Nat
Commun. 6:83992015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wachtel M and Schäfer BW: Targets for
cancer therapy in childhood sarcomas. Cancer Treat Rev. 36:318–327.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bernthal NM, Federman N, Eilber FR, Nelson
SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25
years) of a randomized, prospective clinical trial evaluating
chemotherapy in patients with high-grade, operable osteosarcoma.
Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maki RG: Ifosfamide in the neoadjuvant
treatment of osteogenic sarcoma. J Clin Oncol. 30:2033–2035. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gayyed MF, El-Maqsoud NM, Tawfiek ER, El
Gelany SA and Rahman MF: A comprehensive analysis of CDC20
overexpression in common malignant tumors from multiple organs: Its
correlation with tumor grade and stage. Tumour Biol. 37:749–762.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shang G, Ma X and Lv G: Cell division
cycle 20 promotes cell proliferation and invasion and inhibits
apoptosis in osteosarcoma cells. Cell Cycle. 17:43–52. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Das T, Roy KS, Chakrabarti T, Mukhopadhyay
S and Roychoudhury S: Withaferin A modulates the Spindle assembly
checkpoint by degradation of Mad2-Cdc20 complex in colorectal
cancer cell lines. Biochem Pharmacol. 91:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang L, Niu T, Huang Y, Zhu H, Zhong W,
Lin J and Zhang Y: Compound 331 selectively induces glioma cell
death by upregulating miR-494 and downregulating CDC20. Sci Rep.
5:120032015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Hou Y, Yin X, Su J, Zhao Z, Ye X,
Zhou X, Zhou L and Wang Z: Rottlerin inhibits cell growth and
invasion via down-regulation of Cdc20 in glioma cells. Oncotarget.
7:69770–69782. 2016.PubMed/NCBI
|
|
37
|
Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff
KL, Oh DC, Hathaway N, Dimova N, Cuny GD and King RW: Pharmacologic
inhibition of the anaphase-promoting complex induces a spindle
checkpoint-dependent mitotic arrest in the absence of spindle
damage. Cancer Cell. 18:382–395. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Verma R, Peters NR, D'Onofrio M, Tochtrop
GP, Sakamoto KM, Varadan R, Zhang M, Coffino P, Fushman D, Deshaies
RJ and King RW: Ubistatins inhibit proteasome-dependent degradation
by binding the ubiquitin chain. Science. 306:117–120. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades
N, Wei W, Ding Q and Zhang J: Prostate cancer-associated mutation
in SPOP impairs its ability to target Cdc20 for poly-ubiquitination
and degradation. Cancer Lett. 385:207–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu
T, Liu J, Shaik S, Chen G, Deng J, et al: APC(Cdc20) suppresses
apoptosis through targeting Bim for ubiquitination and destruction.
Dev Cell. 29:377–391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zheng JH, Viacava Follis A, Kriwacki RW
and Moldoveanu T: Discoveries and controversies in BCL-2
protein-mediated apoptosis. FEBS J. 283:2690–2700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
O'Connor L, Strasser A, O'Reilly LA,
Hausmann G, Adams JM, Cory S and Huang DC: Bim: A novel member of
the Bcl-2 family that promotes apoptosis. EMBO J. 17:384–395. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
U M, Miyashita T, Shikama Y, Tadokoro K
and Yamada M: Molecular cloning and characterization of six novel
isoforms of human Bim, a member of the proapoptotic Bcl-2 family.
FEBS Lett. 509:135–141. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Correia C, Lee SH, Meng XW, Vincelette ND,
Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging
understanding of Bcl-2 biology: Implications for neoplastic
progression and treatment. Biochim Biophys Acta. 1853:1658–1671.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sionov RV, Vlahopoulos SA and Granot Z:
Regulation of Bim in health and disease. Oncotarget. 6:23058–23134.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Akiyama T, Dass CR and Choong PF:
Bim-targeted cancer therapy: A link between drug action and
underlying molecular changes. Mol Cancer Ther. 8:3173–3180. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tan TT, Degenhardt K, Nelson DA, Beaudoin
B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM and White E:
Key roles of BIM-driven apoptosis in epithelial tumors and rational
chemotherapy. Cancer Cell. 7:227–238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Simpson CD, Anyiwe K and Schimmer AD:
Anoikis resistance and tumor metastasis. Cancer Lett. 272:177–185.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Woods NT, Yamaguchi H, Lee FY, Bhalla KN
and Wang HG: Anoikis, initiated by Mcl-1 degradation and Bim
induction, is deregulated during oncogenesis. Cancer Res.
67:10744–10752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen K, Tu Y, Zhang Y, Blair HC, Zhang L
and Wu C: PINCH-1 regulates the ERK-Bim pathway and contributes to
apoptosis resistance in cancer cells. J Biol Chem. 283:2508–2517.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Iurlaro R and Muñoz-Pinedo C: Cell death
induced by endoplasmic reticulum stress. FEBS J. 283:2640–2652.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Savry A, Carre M, Berges R, Rovini A,
Pobel I, Chacon C, Braguer D and Bourgarel-Rey V: Bcl-2-enhanced
efficacy of microtubule-targeting chemotherapy through Bim
overexpression: Implications for cancer treatment. Neoplasia.
15:49–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cardona AF, Rojas L, Wills B, Arrieta O,
Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C,
Reguart N, et al: BIM deletion polymorphisms in Hispanic patients
with non-small cell lung cancer carriers of EGFR mutations.
Oncotarget. 7:68933–68942. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Costa C, Molina MA, Drozdowskyj A,
Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R,
Massuti B, Wei J, Moran T, et al: The impact of EGFR T790M
mutations and BIM mRNA expression on outcome in patients with
EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the
randomized phase III EURTAC trial. Clin Cancer Res. 20:2001–2010.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gambichler T, Rooms I, Scholl L,
Stockfleth E, Stucker M and Sand M: BH3-only protein Bim predicts
advanced stage of cutaneous melanoma. J Eur Acad Dermatol Venereol.
30:1926–1929. 2016.PubMed/NCBI
|
|
56
|
Kim BW, Cho H, Ylaya K, Kitano H, Chung
JY, Hewitt SM and Kim JH: Bcl-2-like protein 11 (BIM) expression is
associated with favorable prognosis for patients with cervical
cancer. Anticancer Res. 37:4873–4879. 2017.PubMed/NCBI
|
|
57
|
Zhang L, Jiang T, Li X, Wang Y, Zhao C,
Zhao S, Xi L, Zhang S, Liu X, Jia Y, et al: Clinical features of
Bim deletion polymorphism and its relation with crizotinib primary
resistance in Chinese patients with ALK/ROS1 fusion-positive
non-small cell lung cancer. Cancer. 123:2927–2935. 2017. View Article : Google Scholar : PubMed/NCBI
|
